The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Open accessAbstract
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, there is no reliable biomarker for predicting BLCA immunotherapy efficiency.”
From TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance (2025) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cited by
Sorted by citations
Items 401–500 of 1,002
Li, N., Zhou, Z.-H., Li, F., Sang, J., Han, Q., Lv, Y., Zhao, W., Li, C., & Liu, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.17546 · Cited by 42
Kurozumi, S., Fujii, T., Matsumoto, H., Inoue, K., Kurosumi, M., Horiguchi, J., & Kuwano, H. (2017) · Medical Molecular Morphology · doi:10.1007/s00795-017-0170-y · Cited by 42
Peskov, K. V., Azarov, I., Chu, L., Voronova, V., Kosinsky, Y., & Helmlinger, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00924 · Cited by 42
Namikawa, K., Takahashi, A., Mori, T., Tsutsumida, A., Suzuki, S., Motoi, N., Jinnai, S., Kage, Y., Mizuta, H., Muto, Y., et al. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000617 · Cited by 42
Yan, L., Wang, Z., Cui, C., Guan, X., Dong, B., Zhao, M., Wu, J., Tian, X., & Hao, C. (2019) · Cancer Science · doi:10.1111/cas.14161 · Cited by 42
Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma
Ramzy, G. M., Koessler, T., Ducrey, E., McKee, T., Ris, F., Buchs, N. C., Rubbia‐Brandt, L., Dietrich, P., & Nowak-Sliwinska, P. M. (2020) · Cancers · doi:10.3390/cancers12061423 · Cited by 45
Zheng, X., Liu, Z., Mi, M., Wen, Q., Wu, G., & Zhang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734853 · Cited by 44
Svatoň, M., Zemanová, M., Skřičková, J., Jakubíková, L., Kolek, V., Kultan, J., Koubková, L., Bejčková, A., Salajka, F., Hrnčiarik, M., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.13048 · Cited by 41
Schreiber, L.-M., Urbiola, C., Das, K., Spiesschaert, B., Kimpel, J., Heinemann, F., Stierstorfer, B., Müller, P., Petersson, M., Erlmann, P., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0574-7 · Cited by 43
Iwata, T. N., Sugihara, K., Wada, T., & Agatsuma, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222280 · Cited by 41
Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
Yuan, S., Liu, Y., Till, B. G., Song, Y., & Wang, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563653 · Cited by 40
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030526 · Cited by 43
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
Tian, W., Shan, B., Zhang, Y., Ren, Y., Liang, S., Zhao, J., Zhao, Z., Wang, G., Zhao, X., Peng, D., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2849 · Cited by 40
de Vos, L., Grünwald, I., Bawden, E., Dietrich, J., Scheckenbach, K., Wiek, C., Zarbl, R., Bootz, F., Landsberg, J., & Dietrich, D. (2020) · Epigenetics · doi:10.1080/15592294.2020.1754675 · Cited by 39
Krishnan, T., Tomita, Y., & Roberts‐Thomson, R. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0070 · Cited by 40
Past, Present, and Future of Anticancer Nanomedicine
Kim, K., & Khang, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254774 · Cited by 39
Zhu, C., Xue, J., Wang, Y., Wang, S., Zhang, N., Wang, Y., Zhang, L., Yang, X., Long, J., Yang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109292 · Cited by 41
Johannet, P. M., Liu, W., Fenyö, D., Wind‐Rotolo, M., Krogsgaard, M., Mehnert, J. M., Weber, J. S., Zhong, J., & Osman, I. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0404 · Cited by 40
Gan, J., Lei, J., Li, Y., Lu, M., Yu, X., & Yu, G. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c12166 · Cited by 40
Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
Ijsselsteijn, M. E., Brouwer, T. P., Abdulrahman, Z., Reidy, E., Ramalheiro, A., Heeren, A. M., Vahrmeijer, A. L., Jordanova, E. S., & de Miranda, N. F. C. C. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.113 · Cited by 39
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
Yang, H., Wang, K., Wang, T., Li, M., Li, B., Li, S., & Yuan, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00300 · Cited by 39
Larocca, C. A., LeBoeuf, N. R., Silk, A. W., & Kaufman, H. L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00554-8 · Cited by 40
Tateo, V., Manuzzi, L., Giglio, A. D., Parisi, C., Lamberti, G., Campana, D., & Pantaleo, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239056 · Cited by 41
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology
Sobhani, F., Robinson, R., Hamidinekoo, A., Roxanis, I., Somaiah, N., & Yuan, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188520 · Cited by 41
Cao, Y., Zhou, Y., Pan, J., Zhong, X., Ding, J., Jing, X., & Sun, S. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.130111 · Cited by 39
Combinatorial Power of cfDNA, CTCs and EVs in Oncology
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040870 · Cited by 40
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Carlino, F., Diana, A., Piccolo, A., Ventriglia, A., Bruno, V., Santo, I. D., Letizia, O., Vita, F. D., Daniele, B., Ciardiello, F., et al. (2022) · Cancers · doi:10.3390/cancers14092102 · Cited by 39
de Lima, V. C. C., Corassa, M. P., Saldanha, E. F., Freitas, H., Arrieta, O. G., Raez, L. E., Samtani, S., Ramos-Ramírez, M., Rojas, C., Burotto, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.010 · Cited by 44
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
Li, H., Zhao, A., Li, M., Shi, L., Han, Q., & Hou, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046755 · Cited by 42
Salomon, G., Maza, A., Boulinguez, S., Paul, C. F., Lamant, L., Tournier, É., Mazereeuw‐Hautier, J., & Meyer, N. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16270 · Cited by 38
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Thangarajah, F., Morgenstern, B., Pahmeyer, C., Schiffmann, L. M., Puppe, J., Mallmann, P. K., Hamacher, S., Buettner, R., Alidousty, C., Holz, B., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02915-1 · Cited by 38
Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 37
Sánchez-Gastaldo, A., Muñoz-Fuentes, M. A., Molina‐Pinelo, S., Alonso-García, M., Boyero, L., & Bernabé, R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-156 · Cited by 38
Immune-related adverse events: A bibliometric analysis
Jiang, S., Liu, Y.-G., Zhang, L., Sang, X., Xu, Y., & Lu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096806 · Cited by 38
Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007628 · Cited by 38
Song, Y., Huang, J., Liang, D., Hu, Y., Mao, B., Li, Q., Sun, H., Yang, Y., Zhang, J., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.549777 · Cited by 40
Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
Zheng, S., Song, J., Linghu, D., Yang, R., Liu, B., Xue, Z., Chen, Q., Liu, C., Zhong, D., Hung, M., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79852 · Cited by 37
Xiao, Y., Li, Z., Zhong, N., Cao, L., Liu, B., & Bu, L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101794 · Cited by 41
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316607 · Cited by 45
Yuan, L., Sun, S., Zhang, Q., Li, H., Shen, Z., Hu, C., Zhao, X., Ye, L., Zheng, C.-H., & Huang, D.-S. (2024) · Future Generation Computer Systems · doi:10.1016/j.future.2024.05.030 · Cited by 39
Zhao, S., & Yu, M. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5129 · Cited by 38
Primary CNS lymphoma commonly expresses immune response biomarkers
Ou, A. C., Sumrall, A. L., Phuphanich, S., Spetzler, D. B., Gatalica, Z., Xiu, J., Michelhaugh, S. K., Brenner, A. J., Pandey, M. K., Kesari, S., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa018 · Cited by 37
Sung, M., Zer, A., Walia, P., Khoja, L., Maganti, M. D., Labbé, C., Shepherd, F. A., Bradbury, P. A., Liu, G., & Leighl, N. B. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.30 · Cited by 36
Patel, R. R., Ramkissoon, S. H., Ross, J. S., & Weintraub, L. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28338 · Cited by 36
Kuang, X., Wang, Z., Luo, Z., He, Z., Liang, L., Gao, Q., Li, Y., Xia, K., Xie, Z., Chang, R., et al. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.02.050 · Cited by 38
Yang, R., Sun, L., Li, C.-F., Wang, Y., Xia, W., Liu, B., Chu, Y., Bover, L. C., Vien, L., & Hung, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101821 · Cited by 37
Liu, R., Niu, Y.-L., Liu, C., Zhang, X., Zhang, J., Shi, M., Zou, W., Gu, B., Zhu, H., Wang, D., et al. (2023) · Cancer Science · doi:10.1111/cas.15716 · Cited by 36
Hereditary pancreatic cancer: related syndromes and clinical perspective
Carrera, S., Sancho, A., Azkona, E., Azkuna, J., & López-Vivanco, G. (2017) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-017-0069-6 · Cited by 36
Shin, S., Kim, Y. J., Lee, D., Cho, D., Ko, Y. H., Cho, J., Park, W., Park, D., Kim, S. J., & Kim, W. S. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1573998 · Cited by 36
Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
Scotlandi, K., Hattinger, C. M., Pellegrini, E., Gambarotti, M., & Serra, M. (2020) · Cells · doi:10.3390/cells9040968 · Cited by 41
Liu, H., Xu, R., Gao, C., Zhu, T., Liu, L., Yang, Y., Zeng, H., Huang, Y., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755668 · Cited by 36
Feola, T., Carbonara, F., Verrico, M., Crescenzo, R. M. D., Gianno, F., Colonnese, C., Arcella, A., Alcubierre, D. D., Tomao, F., Esposito, V., et al. (2022) · Cancers · doi:10.3390/cancers14174093 · Cited by 36
Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry
Ying, L., Yan, F., Meng, Q., Yuan, X., Yu, L., Williams, B. R. G., Chan, D. W., Shi, L., Tu, Y., Ni, P., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1311-8 · Cited by 35
Weng, Y. M., Peng, M., Hu, M. X., Yao, Y., & Song, Q. B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s167865 · Cited by 35
Dissecting the Immune Landscape of Acute Myeloid Leukemia
Davidson-Moncada, J. K., Viboch, E., Church, S., Warren, S. E., & Rutella, S. (2018) · Biomedicines · doi:10.3390/biomedicines6040110 · Cited by 34
Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
Brandi, G., & Frega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112699 · Cited by 36
MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer
Jung, E., Choi, J., Kim, J.-S., & Han, T. (2021) · Pharmaceuticals · doi:10.3390/ph14020136 · Cited by 36
Ramos‐Paradas, J., Hernández-Prieto, S., Lora, D., Sanchez, E., Rosado, A., Caniego-Casas, T., Carrizo, N., Enguita, A. B., Muñoz-Jimenez, M. T., Rodriguez, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001904 · Cited by 35
Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 39
Current status and future perspective of radiopharmaceuticals in China
Hu, J., Li, H., Sui, Y., & Du, J. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05615-6 · Cited by 34
Principe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35
The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer
Nishi, M., Yoshikawa, K., Higashijima, J., Tokunaga, T., Kashihara, H., Takasu, C., Ishikawa, D., Wada, Y., & Shimada, M. (2018) · Anticancer Research · doi:10.21873/anticanres.12605 · Cited by 34
Cheng, Y., Li, L., Wei, X., Xu, F., Huang, X., Qi, F., Zhang, Y., & Li, X. (2023) · Cancer Science · doi:10.1111/cas.15745 · Cited by 35
Lao, J., Xu, H., Liang, Z., Luo, C., Shu, L., Xie, Y., Wu, Y., Hao, Y., & Yuan, Y. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152391 · Cited by 34
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 37
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Jung, C. Y., & Antonia, S. J. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.0120 · Cited by 34
Gastric Cancer in the Era of Immune Checkpoint Blockade
Figueroa-Protti, L., Soto-Molinari, R., Calderón-Osorno, M., Mora, J., & Alpízar‐Alpízar, W. (2019) · Journal of Oncology · doi:10.1155/2019/1079710 · Cited by 34
Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer
Kwon, M. J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01189-y · Cited by 33
Cao, J., Guo, Q., Guan, G., Zhu, C., Zou, C., Zhang, L., Cheng, W., Wang, G., Cheng, P., Wu, A., et al. (2020) · Aging · doi:10.18632/aging.102706 · Cited by 34
Wang, H., Guo, J., Shang, X., & Wang, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106574 · Cited by 36
Girolami, I., Pantanowitz, L., Munari, E., Martini, M., Nocini, R., Bisi, N., Molteni, G., Marchioni, D., Ghimenton, C., Brunelli, M., et al. (2020) · Head & Neck · doi:10.1002/hed.26339 · Cited by 34
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Wang, Z., Guo, X., Gao, L., Wang, Y., Guo, Y. C., Xing, B., & Ma, W. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.12.012 · Cited by 35
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Zouein, J., Kesrouani, C., & Kourié, H. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0336 · Cited by 37
Yang, C., Zhang, Z., Tang, X., Zhang, X., Chen, Y., Hu, T., Zhang, H., Guan, M., Zhang, X., & Wu, Z. (2021) · Human Cell · doi:10.1007/s13577-021-00630-z · Cited by 35
E-cadherin on epithelial–mesenchymal transition in thyroid cancer
Zhu, X., Wang, X., Gong, Y., & Deng, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02344-6 · Cited by 36
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Patterson, A., & Auslander, N. (2022) · Nature Communications · doi:10.1038/s41467-022-32838-4 · Cited by 32
Huang, Y., Zhao, J. J., Soon, Y. Y., Wong, A. S. C., Aminkeng, F., Ang, Y. L. E., Asokumaran, Y., Low, J. L., Lee, M., Choo, J. R. E., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14667 · Cited by 34
Wu, Z., Lei, K., Li, H., He, J., & Shi, E. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03686-z · Cited by 34
Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer
Xu, C., Song, L., Peng, H. C., Yang, Y., Liu, Y., Pei, D., Guo, J., Liu, N., Liu, J., Li, X., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.963455 · Cited by 33
Huang, Z., Guo, Y. H., Li, B., Shen, M., Yi, Y., Li, L., Zhao, X., & Yang, L. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00713-z · Cited by 33
Li, B., Su, J. S., Liu, K., & Hu, C. (2024) · European Journal of Radiology Open · doi:10.1016/j.ejro.2024.100549 · Cited by 35
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
Li, J., Shi, D., Li, S., Shi, X., Liu, Y., Zhang, Y., Wang, G., Zhang, C., Xia, T., Piao, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06563-3 · Cited by 36
Aue, G., Sun, C., Liu, D., Park, J.-H., Pittaluga, S., Tian, X., Lee, E., Soto, S., Valdez, J., Marić, I., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800570 · Cited by 33
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
Zemek, R. M., Fear, V. S., Forbes, C., de Jong, E., Casey, T. H., Boon, L., Lassmann, T., Bosco, A., Millward, M., Nowak, A. K., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0299-3 · Cited by 31
Uraki, S., Ariyasu, H., Doi, A., Takeshima, K., Morita, S., Inaba, H., Furuta, H., Fukuhara, N., Inoshita, N., Nishioka, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082831 · Cited by 32
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida, D. V. P., Fong, L. H., Rettig, M. B., & Autio, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278853 · Cited by 34
Chen, L., Shi, X., Zhao, J., He, Q., Fan, Y., Xu, W., Shao, Y. W., Yu, X., & Jin, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00480 · Cited by 33
Emerging role of microbiota in immunomodulation and cancer immunotherapy
Singh, R. P., Bashir, H., & Kumar, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.008 · Cited by 34
Comprehensive profiling of immune-related genes in soft tissue sarcoma patients
Hu, C., Chen, B., Huang, Z., Liu, C., Ye, L., Wang, C., Tong, Y., Yang, J., & Zhao, C. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02512-8 · Cited by 33
Jiang, J., Ding, Y., Wu, M., Chen, Y., Lyu, X., Lü, J., Wang, H., & Teng, L. (2020) · Cancer Medicine · doi:10.1002/cam4.3481 · Cited by 34
Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Arai, H., Baca, Y., Battaglin, F., Kawanishi, N. K., Wang, J., Soni, S., Zhang, W., Millstein, J., Johnston, C., Goldberg, R. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0318 · Cited by 33
Expected and paradoxical effects of obesity on cancer treatment response
Gallo, M., Adinolfi, V., Barucca, V., Prinzi, N., Renzelli, V., Barrea, L., Giacinto, P. D., Ruggeri, R. M., Sesti, F. F., Arvat, E., et al. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09597-y · Cited by 34
Kano, M., Hihara, J., Tokumoto, N., Kohashi, T., Hara, T., Shimbara, K., & Takahashi, S. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01833-4 · Cited by 36
Nielsen, T. J., Ring, B. Z., Seitz, R. S., Hout, D. R., & Schweitzer, B. L. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06438 · Cited by 33
Cao, R., Ma, B., Wang, G., Xiong, Y., Tian, Y., & Yuan, L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.011 · Cited by 33
Vaccine-Based Immunotherapy for Head and Neck Cancers
Beyaert, S. P., Machiels, J., & Schmitz, S. (2021) · Cancers · doi:10.3390/cancers13236041 · Cited by 32
Rong, X., Jin-yu, L., Liu, Y., Wang, Z., Zeng, D., Li, Y., Li, S., Wu, J., Shen, Z., Shi, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.802257 · Cited by 34
Metadata
- Authors
- Gibney, G. T., Weiner, L. M., & Atkins, M. B.
- Affiliations
- Georgetown University Medical Center (US)
- Corresponding author
- Gibney, Geoffrey T
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 17
- Issue
- 12
- Pages
- e542-e551
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5702534
- OpenAlex
- W2559382297
- Cited by
- 1,635
- References
- 76
- Citations by year
- 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA050633, P30CA051008)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
- MeSH terms
- Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
